• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Late complications of pancreas transplant

    2020-03-11 05:48:02JavierMaupoeyIbezAndreaBoscRobledoRafaelpezAndujar
    World Journal of Transplantation 2020年12期

    Javier Maupoey Ibá?ez, Andrea Boscà Robledo, Rafael López-Andujar

    Javier Maupoey Ibá?ez, Andrea Boscà Robledo, Rafael López-Andujar, Hepato-Pancreatico-Biliary Surgery and Transplant Unit, La Fe University Hospital, Valencia 46026, Spain

    Abstract To summarize the long-term complications after pancreas transplantation that affect graft function, a literature search was carried out on the long-term complications of pancreatic transplantation, namely, complications from postoperative 3rd mo onwards, in terms of loss of graft function, late infection and vascular complications as pseudoaneurysms. The most relevant reviews and studies were selected to obtain the current evidence on these topics. The definition of graft failure varies among different studies, so it is difficult to evaluate, a standardized definition is of utmost importance to know the magnitude of the problem in all worldwide series. Chronic rejection is the main cause of long-term graft failure, occurring in 10% of patients. From the 3rd mo of transplantation onwards, the main risk factor for late infections is immunosuppression, and patients have opportunistic infections like: Cytomegalovirus, hepatitis B and C viruses, Epstein-Barr virus and varicella-zoster virus; opportunistic bacteria, reactivation of latent infections as tuberculosis or fungal infections. Complete preoperative studies and serological tests should be made in all recipients to avoid these infections, adding perioperative prophylactic treatments when indicated. Pseudoaneurysm are uncommon, but one of the main causes of late bleeding, which can be fatal. The treatment should be performed with radiological endovascular approaches or open surgery in case of failure. Despite all therapeutic options for the complications mentioned above, transplantectomy is a necessary option in approximately 50% of relaparotomies, especially in lifethreatening complications. Late complications in pancreatic transplantation threatens long-term graft function. An exhaustive follow-up as well as a correct immunosuppression protocol are necessary for prevention.

    Key Words: Pancreas transplantation; Pancreas allograft failure; Pancreas transplant rejection; Pseudoaneurysm; Allograft pancreatectomy

    INTRODUCTION

    Pancreas transplantation is currently the most effective method to establish durable normoglycemia for patients with diabetes mellitus[1], and therefore achieves the benefits demonstrated with intensive insulin therapy, but without hypoglycemic complications derived from that treatment. Pancreatic graft loss may occur due to several complications, such as technical failure in the early postoperative period, but also late complications (which occur from postoperative 3rd mo onwards), among which the most relevant are chronic rejection, late infections and vascular complications as pseudoaneurysms. In recent years, pancreatic graft long-term survival has improved, with a half-life longer than 14 years in simultaneous pancreas and kidney (SPK) transplantation, which is the most frequent modality of pancreas transplantation as it is associated with better allograft survival[2]. In this review, we will describe the late complications of pancreas transplant and recent trends in their prevention, diagnosis and treatment.

    LOSS OF GRAFT FUNCTION

    The Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) Pancreas Transplantation Committee approved precise definitions of pancreas graft failure in early 2018. Some of the definitions are concrete, such as a recipient’s transplanted pancreas is removed, a recipient re-registers for pancreas transplant, a recipient registers for an islet transplant after undergoing pancreas transplant, or a recipient dies. Pancreas graft failure can also be defined if a recipient’s total insulin use is greater than or equal to 0.5 units/kg/d for a consecutive 90 d. The latter definition may be problematic if the recipient’s starting insulin dose is less than 0.5 units/kg/d[2].

    Recently the consensus report from the International Pancreas & Islet Transplant Association and European Pancreas & Islet Transplantation Association[3]defined the outcomes of beta–cell (b-cell) replacement therapy: Optimal b-cell graft function is defined by near-normal glycemic control (HbA1c ≤ 6.5% [48 mmol/mol]) without severe hypoglycemia or requirement for insulin or other antihyperglycemic therapy, and with an increase over pretransplant measurement of C-peptide. Good b-cell graft function requires HbA1c < 7.0% (53 mmol/mol) without severe hypoglycemia and with a significant (> 50%) reduction in insulin requirements and restoration of clinically significant C-peptide production. Marginal b-cell graft function is defined by failure to achieve HbA1c < 7.0% (53 mmol/mol), the occurrence of any severe hypoglycemia, or less than 50% reduction in insulin requirements when there is restoration of clinically significant C-peptide production documented by improvement in hypoglycemia awareness/severity, or glycemic variability/lability. A failed b-cell graft is defined by the absence of any evidence for clinically significant C-peptide production. Optimal and good functional outcomes are considered successful clinical outcomes.

    Although these newer definitions have not yet been reflected, reported early overall rate of pancreas graft failure (within the first 90 d) in 2018 was 5.9%, and 5-year pancreas graft survival rates were 73% for SPK, 65% for pancreas after kidney (PAK), and 53% for pancreas transplant alone (PTA)[2]. These results are similar in Spain, with a 5-year graft survival rate of 72%-74% for SPK[4].

    Adverse technical and immunological events within the 1styear need to be avoided under all circumstances; what happens in the 1styear posttransplant has a very strong impact on long-term graft function[5]. The main cause of pancreas graft loss within the first 3 mo usually is technical failure: Graft thrombosis (10%-35%) followed by intraabdominal infections and pancreatitis[6]. An adequate immunosuppression therapy with tight control is recommended to avoid pancreas allograft rejection, since it is also one of the main causes of graft failure. Acute rejection usually develops 1 wk to 3 mo after transplantation but can occur earlier or later, it is difficult to diagnose, but may be suspected when loss of allograft function (hyperglycemia) is associated with high level of serum amylase and/orlipase. Early detection is essential to institute antirejection treatment and avert graft failure. Incidence in OPTN/UNOS data of a first rejection episode is improving over time, with low rates respect previous data for all categories of pancreas transplant, in 2016-2017 in the United States it was: 11.7%, 19.2%, and 12.4% following PAK, PTA and SPK respectively[2]. In the same way, global incidence of rejection in Spain series was 10.9% in SPK during last decade[4]. These low rejection rates clearly reflect ongoing improvements in immunosuppression protocols. In fact, the avoidance of acute rejection episodes is probably the single highest impact on excellent long-term function[5].

    There is some controversy regarding immunosuppressive treatment in pancreas transplantation. Standard protocols include use of induction therapy followed by maintenance immunosuppression, but the amount, frequency and duration of each therapy, especially the induction treatment has not been clearly defined, which consist in T-cell depleting agent (e.g., antithymocyte globulin and alemtuzumab), even though it has been adopted by most centers (> 80%). Maintenance immunosuppressive therapy for pancreatic transplantation is similar for that used for kidney transplantation. A combination of a calcineurin inhibitor (predominantly tacrolimus), an antimetabolite (mycophenolate mofetil or mycophenolate sodium), is associated to low-dose corticosteroids therapy in approximately 60% of the centers[2]. However, taking into account the metabolic side effects as well as the increased risk of infection associated with the use of steroids[7], some studies have suggested early steroid withdrawal or steroid free regimens in these patients, particularly after the introduction of induction therapy with T-cell depleting agents, but there is currently insufficient evidence for the benefits and harmsof this therapy[8]. There is also a trend to incorporate mammalian target of rapamycin (mTOR) inhibitors over mycophenolate in combination with tacrolimus into immunosuppressive protocol, because rapamycin appears to be more effective in preventing acute rejection, but it must be weighed against its potential negative metabolic consequences and the accentuation of the nephrotoxicity of the calcineurin inhibitor and wound-healing complications[9-11], so at the moment it has not been widely adopted. Future research should focus on developing personalized immune assessment of transplant patients, through noninvasive tests of immunological biomarkers to monitor the recipient’s immune status[12]. These tests will permit recipient-specific tailored immunosuppressive protocols, based on their immunity response and individual risk, minimizing the complications of excessive immunosuppression while maintaining a low incidence of rejection.

    Chronic rejection remains the main cause of long-term graft failure after 1 year, occurring in 10% of patients[13,14]. It may be the result of recurrent episodes of acute rejection with posterior fibrosis, atrophy, and eventual loss of graft function. Therefore, effective immunosuppression protocols and close monitoring of pancreas and kidney allograft function are the best way to prevent it. The image tests findings of acute and chronic rejections are relatively nonspecific and unreliable, making it difficult to diagnose[15]. Diagnostic confirmation must be performed by needle core pancreas allograft biopsy, preferably percutaneous ultrasound-guided biopsy[16]. The Banff schema for grading pancreas allograft rejection based on pathological findings, differentiate the type (T-cell-mediated rejection or antibody-mediated pancreas allograft rejection) and the grade (mild, moderate, and severe) with a high diagnostic accuracy, helping to select the appropriate treatment in each case[17,18].

    Given the possibility of chronic rejection, type 1 diabetes mellitus recurrence should also be suspected, which is an infrequent entity, appearing approximately in 3%-7% of properly immunosuppressed patients[19]. It occurs due to the presence of antibodies against pancreatic beta cells in the recipient (type 1 diabetes-associated autoantibodies to the autoantigens GAD65, IA-2, and ZnT8) causing destruction of the pancreatic islets (insulitis). Usually the antibody conversion precede hyperglycemia by a variable length of time, and negative autoimmunity prior to transplantation does not ensure that autoimmune diabetes will not recur. Unlike rejection, serum amylase and lipase levels usually do not rise, and there is no effective treatment, as the increase in immunosuppression does not improve the progression of islet autoimmunity. Diagnostic confirmation must be performed by percutaneous biopsy, in which a variable degree of insulitis and loss of insulin staining must be seen, sometimes associated to minimal to moderate and rarely severe pancreas and/or kidney transplant rejection[20].

    The 5-year mortality for SPK in OPTN/UNOS data[2]and Spanish series[4]ranges over 7% to 8%. Long-term mortality data reflect the high cardiovascular comorbidity in this population, with 10-year mortality 26.8%, 20.1%, and 25.3% for PAK, PTA, and SPK, respectively. Despite effective glycemia control after pancreas transplantation delays progression of microvascular complications and improves survival in diabetic patients, cardiovascular comorbidity is the main factor that threatens long-term survival of pancreas transplant patients[5], so its optimal control is another of the priority objectives in the follow up of this patients.

    There has been controversy regarding transplant center volume and the risk of short and long-term pancreas graft failure, so it has been analyzed by several studies, highlighting that patient and graft survival after pancreas transplantation are superior in higher volume centers (> 13 transplants/year) than in lower volume centers[21,22], or at least equal even though they transplant organs with the highest pancreas donor risk index[23]. The explanation for inferior outcomes in low-volume centers is likely to be complex, but center volume could be a surrogate marker for adequate recipient selection, surgical expertise, multidisciplinary preoperative, and postoperative inpatient and outpatient care, and appropriate long-term follow-up. Actually, approximately two-thirds of pancreas transplants are performed at programs that perform more than 10 transplants per year, and these numbers have not changed substantially over the past decade[2], this may have contributed to explain the improvement of global pancreas allograft and patient survival throughout last years, demonstrating a better management in these demanding patients over time.

    CHRONIC INFECTION

    Approximately 63% of pancreas transplant recipients develop a serious infection during the first 5 years of follow-up[24]. Many of the infections in pancreas transplantation follow a typical temporal pattern. Three periods have been described based on the predominance of certain infections: In the first period (1stmo), bacterial infections derived from the surgical procedure are typical. In the second period (2-6 mo), the main risk factor is immunosuppression, and patients basically have de novo opportunistic infections or reactivation of latent diseases: Cytomegalovirus (CMV), herpes simplex virus type 6 (VHV), hepatitis B and C viruses (HBV/HCV), Epstein-Barr virus (EBV) and varicella-zoster virus (VZV); and opportunistic bacteria:Pneumocystis jirovecipneumonia, Nocardia, Listeria monocytogenes,Toxoplasma gondii, and fungal infections, among others. During the third period (after the 6thmo), in patients with good allograft function, the majority of infections are those acquired in the community, similar to the general population, although opportunistic infections may also occur, by reactivation of certain latent viruses (BK virus, CMV…)[7]. In addition, tumors related to viral infections such as vulgar warts and post-transplant lymphoproliferative diseases, especially due to EBV, may develop in this period[25].

    Prevention of infections

    Prophylaxis before transplant:Prevention of infection begins with the adequate selection of the donor and a rigorous evaluation of the recipient with an exhaustive physical examination and study of viral serological markers: CMV, EBV, VZV, HBV, HCV, HIV toxoplasmosis,Treponema pallidumserology, and some others that can vary according to the epidemiology of each geographic area. This permits us to diagnose and treat active infections in the candidates, make decisions about their acceptance or exclusion, and identify the risk factors. Moreover, vaccinations must be completed before the transplantation according to the protocol of each center and geographical area[24].

    Perioperative prophylaxis:At the time of the transplant surgery, prophylactic administration of antibiotics like cephalosporins, or ampicillin-sulbactam as an alternative, every 2 h during surgery, and maintenance until 48 h after surgery is recommended. Antifungals (fluconazole) are also associated in a single dose during surgery, and in postoperative prophylaxis regimen up to 14 d in cases of increased risk of infection[26]. The choice of therapeutic agent, both for prophylaxis and for empirical treatment, will also depend on the incidence and type of microorganisms isolated in each center.

    The use of cotrimoxazole at low doses until the 6thmo post-transplant has decreased the incidence ofPneumocystis pneumonia[27]. Likewise, it constitutes an excellent prophylaxis to avoid infection by intracellular bacteria, such asListeria monocytogenesandNocardia spp.

    CMV prophylaxis and monitoring after transplantation:CMV infections are one of the most frequent complications affecting solid organ transplant recipients, conveying higher risk of graft loss, morbidity and mortality. Given that the CMV serostatus of donor and recipient (D/R) are key predictors of the risk of CMV after transplant, and guide decisions on antiviral prophylaxis or preemptive treatment. A measurement of CMV-specific IgG should be performed, and if the donor or recipient is seronegative during the pretransplant evaluation, serology should be repeated at the time of the transplantation. According to the guidelines of the latest international consensus of 2018 on the management of CMV in solid organ transplants[28], in pancreas transplantation, prophylactic treatment with valganciclovir is recommended based on the risk of CMV infection (Table 1). Other valid option is the preemptive therapy, which consists in the monitoring of CMV viral load in blood at regular intervals (weekly) to detect early viral replication. Once a predetermined assay threshold is achieved (optimally prior to the development of symptoms), antiviral treatment is begun, which should prevent progression to clinical disease. Moreover, there are specific situations that increase the risk of CMV infection, such as in cases where antilymphocyte antibodies for induction are administered, plasmapheresis or HIV infection patients. In these cases, it is also mandatory to administer a prophylactic treatment with valganciclovir, and duration will depend on the degree of immunosuppression of the patient. However, there are resistances associated with currently available therapeutics, as there are series with pancreas-kidney transplant high risk patients (D+/R-) who developed CMV infection/disease despite correct CMV prophylaxis in up to 44%[29]. Novel antivirals therapies are emerging including letermovir, maribavir, and brincidofovir at various states of research development. Future research are needed to evaluate combination therapies for prophylaxis and treatment as well as adjunctive therapies[30].

    Furthermore, there is moderate to high-quality evidence of a lower risk of CMV infection in transplant recipients with mTOR inhibitor-based immunosuppressive therapy compared with calcineurin inhibitor-based regimens, therefore a combination of a mTOR inhibitor and a reduced dose of calcineurin inhibitor could be a good alternative in high risk CMV infection patients[31,32].

    Prevention of tuberculosis infection:In the pre-transplant evaluation, the possibility of latent tuberculosis infection should be assessed by performing the tuberculin skin test (TST), and/or tests based on the secretion of interferon gamma by memory T cells in response to mycobacterial antigens (interferon gamma release assays) as QuantiFERON TM-TB Gold test. If the result is positive in any of these tests, a prophylactic treatment with isoniazid should be administered, and active tuberculosis infection should also be ruled out. If tuberculosis infection is confirmed, the transplant would be contraindicated until the infection is cured.

    According to the guidelines of the European Society for Clinical Microbiology and Infectious Diseases[33], if the TST or QuantiFERON are positive, or the chest X-ray shows lesions of previous tuberculosis, and there is no evidence that the patient have received a correct treatment, chemoprophylaxis with isoniazid for 9 mo should be administered.

    PSEUDOANEURYSM

    Pseudoaneurysms (PA) occur due to a laceration or disruption of the arterial wall caused by chemical damage due to the exposure to enzymes in the event of pancreatic fistulas or infections with peripancreatic collections, chronic rejections, surgical trauma or biopsies, causing a bleeding into an external fibrous compartment that will contain the hematoma. Vascular anastomoses are the most frequent areas affected by PA, but those caused by biopsies usually occur in the pancreatic parenchyma, and can lead to arteriovenous fistulas.

    Table 1 Recommended approaches for cytomegalovirus prevention for adult pancreas transplant

    Although PA are infrequent entities, they are one of the main causes of late bleeding, sometimes years after transplantation, which can be lethal. PA tend to debut first with mild digestive hemorrhages, called sentinel bleeding, which can progress to an arteriovenous or arterioenteric fistula[34], preceding of fatal hemorrhage. PA are difficult to detect before the development of massive hemorrhage due to the absence or mildness of the previous symptoms. For this reason, graft control with doppler ultrasonography in the follow up should be performed[35]. Once PA is suspected or demonstrated at ultrasonography, the full anatomy of the PA is best displayed with volumetric high-spatial-resolution CT scanning (angio-CT) or magnetic resonance angiography[14]. Such imaging display is required before planning the treatment (Figure 1).

    Current treatment of PA firstly should be performed with radiological endovascular approaches, when possible. Although there is still a lack of reliable data due to the relatively little experience of this approach in pancreas transplant complications, endovascular procedures are becoming more frequently used as they are safe and feasible, but technically demanding. One of the main risks of this approach is the renal function damage caused by contrast agent, but the risk of kidney graft function deterioration, as well as of bleeding due to the high dose of heparin used, seems to be lower than with open surgery[36].

    When a PA is diagnosed, elective treatment should be performed to prevent the potential life- and graft-threatening bleeding. The choice between minimally invasive and open surgical repair should be individualized depending on the site of the lesion, the patient status and the multidisciplinary team experience[37,38]. Nevertheless, at the time of acute bleeding, immediate treatment is essential: Endovascular approach with a covered stenting of the involved artery to exclude the PA may provide immediate vascular control in these situations. But if an arteriovenous fistula exists, embolization with microparticles is the treatment of choice[39]. These procedures can be either a definitive treatment[40]or a bridge therapy to posterior open repair[41,42], since rebleeding or necrosis and posterior loss of graft function are not uncommon. For this reason, on many occasions (especially in infections) allograft transplantectomy including the graft vascular anastomosis is performed, requiring sometimes an extra anatomic bypass to maintain blood flow of the lower limb[43].

    ALLOGRAFT PANCREATECTOMY: INDICATIONS AND SURGICAL TECHNIQUE

    Indications

    Surgical complications after pancreas transplantation and later relaparotomies are frequent (25%-30%) and the main cause are thrombosis, bleeding, infection, pancreatitis and bowel obstruction. Unfortunately, it implies allograft pancreatectomy in 50% of cases, and occasionally patient death[44]. The management of such complications has evolved from a low threshold to remove the graft, to considering options for graft preservation through the new antimicrobial and immunosuppressive therapies, as well as the imaging techniques that permit an early diagnosis and imageguided invasive procedures. However, the need to perform a transplantectomy is a necessary situation in some occasions, especially in life-threatening complications. Currently there are no guidelines or consensus that clearly indicate to the surgeon when and how it should be performed, but as a general rule, safety of the recipient should be considered as the main factor to take into account.

    Figure 1 Pseudoaneurysm in the right iliac artery anastomosis of the pancreas graft in a simultaneous pancreas and kidney patient (arrows).

    Thrombosis-related graft necrosis, severe pancreatitis, and uncontrolled duodenal leak constitute the main indications for allograft pancreatectomy during the first 4 wk after transplantation[44]. And late allograft pancreatectomy is usually reserved for recipients with failed grafts, predominantly from chronic rejection who have abdominal and flank pain, gastrointestinal symptoms and/or fever[45]. The rate of allograft pancreatectomy for late graft failure ranges from 25% to 50%, and in these cases the symptoms associated with the failed pancreas graft, risk of formation of arterioenteric fistula, and candidacy for potential retransplantation need to be cautiously evaluated in order to appropriately select the timing and the surgical approach for allograft pancreatectomy[46]. Recent studies show a marked fall in morbidity and mortality of allograft pancreatectomy, and emphasize the benefits of early retransplantation in appropriate candidates[47]. However, late pancreas retransplantation is also possible, although it has been associated with poorer allograft survival[48], in recent series technical failure and patient death for primaryvspancreas retransplants are similar in highly selected patients, if they are carried out in experienced centers[49-51].

    Surgical technique

    In cases of early transplantectomy, adhesions are not usually a problem. In order to gain rapid exposure of the vascular anastomoses, it is helpful to divide the enteric anastomosis first using a gastrointestinal anastomosis stapler by resecting the jejunum segment together with the duodenum (in enteric drainage transplants). The portal vein and iliac artery of the graft are clamped, divided, and oversewn. And then, the intestinal transit is reestablished with a jejunal anastomosis.

    In cases of late transplantectomy, it can be performed in isolation or associated with a pancreas retransplantation. The operative field can be complex due to the adhesions, and in many occasions the graft will be shrunken, fibrosed, and poorly perfused, and there may be extensive adhesions to the retroperitoneum, making it difficult to identify. When graft pancreatectomy is performed as an isolated operation, the complete exposure of the recipient vasculature is often unnecessary. But when a failed allograft is removed at the time of retransplantation, the initial pancreas graft must be carefully explored and dissected away from the recipient iliac vessels and the inferior vena cava, in order to identify appropriate sites for implantation of the new pancreas graft. The allograft portal vein and iliac artery, once identified, are divided and oversewn taking care to avoid compromising the recipient arterial lumen. In cases where is not possible to preserve the recipient iliac vessels blood flow due to their involvement, as in PA or arterioenteric fistulas, an endovascular placement of a covered stent can be placed at the level of the anastomotic site. Alternatively, if it is not effective, an angioplasty with bovine pericardial patch can be done in cases of small defects of the vessel wall. Otherwise, a reconstruction with a synthetic prosthesis or cadaver graft if available in cases of major vessel damage is a valid option[52].

    CONCLUSION

    Pancreas transplantation is a complex and technically demanding procedure. Early complications may occur, mostly due to technical failure as thrombosis, intraabdominal infections and pancreatitis. But late complications also entail a high percentage of graft losses, particularly secondary to chronic rejection or even late infections. PA are uncommon, but one of the main causes of late bleeding, which can be fatal. A high index of suspicion is needed to detect it, and once PA is diagnosed, the treatment should be performed, preferably with radiological endovascular approaches or open surgery in case of failure. Despite all therapeutic options for the complications mentioned above, transplantectomy is necessary in approximately 50% of relaparotomies, especially in life-threatening complications. Although pancreas retransplantation can be performed later in selected patients. Close monitoring of graft function and clinical and radiological surveillance, as well as new advances in the immunosuppression protocols, individualized according to the patient′s situation are crucial to prevent rejection, improving pancreas graft survival, as well as the optimal control of cardiovascular comorbidity to achieve better patient long-term survival.

    一区在线观看完整版| xxx大片免费视频| 99国产精品免费福利视频| a级毛片在线看网站| 国产成人影院久久av| 久久中文字幕一级| 精品福利永久在线观看| 中文欧美无线码| 国产精品 欧美亚洲| 日本猛色少妇xxxxx猛交久久| 91精品国产国语对白视频| 亚洲成人免费电影在线观看 | 如日韩欧美国产精品一区二区三区| 国产精品三级大全| 777久久人妻少妇嫩草av网站| 亚洲第一av免费看| 高清黄色对白视频在线免费看| 久久天躁狠狠躁夜夜2o2o | 一本一本久久a久久精品综合妖精| 久久久久久久久久久久大奶| 亚洲欧洲精品一区二区精品久久久| 免费在线观看视频国产中文字幕亚洲 | 50天的宝宝边吃奶边哭怎么回事| 99九九在线精品视频| 精品国产超薄肉色丝袜足j| 久久久久久久大尺度免费视频| 日韩电影二区| 亚洲av国产av综合av卡| 国产一区二区在线观看av| 在线av久久热| 亚洲午夜精品一区,二区,三区| 在线观看一区二区三区激情| 欧美精品一区二区大全| 丰满人妻熟妇乱又伦精品不卡| a 毛片基地| 日韩 欧美 亚洲 中文字幕| 51午夜福利影视在线观看| 一本—道久久a久久精品蜜桃钙片| 9191精品国产免费久久| 日本欧美视频一区| 亚洲激情五月婷婷啪啪| 黄片播放在线免费| 欧美成人精品欧美一级黄| 午夜福利,免费看| 国产精品国产三级专区第一集| 91麻豆av在线| 国产日韩一区二区三区精品不卡| 一区二区av电影网| 国产极品粉嫩免费观看在线| 中文欧美无线码| 黄色片一级片一级黄色片| xxx大片免费视频| 久久青草综合色| 欧美性长视频在线观看| 婷婷色av中文字幕| 国产在线观看jvid| 免费看不卡的av| 久久久国产精品麻豆| 久久精品成人免费网站| 国产一区二区在线观看av| 免费av中文字幕在线| 少妇猛男粗大的猛烈进出视频| 亚洲欧美精品综合一区二区三区| 男人舔女人的私密视频| 国产精品二区激情视频| 在线看a的网站| 男人爽女人下面视频在线观看| 国产精品一二三区在线看| 久久久精品免费免费高清| 满18在线观看网站| 一边亲一边摸免费视频| 亚洲专区国产一区二区| 午夜影院在线不卡| 黄频高清免费视频| 国产成人欧美在线观看 | 免费在线观看视频国产中文字幕亚洲 | 日本欧美国产在线视频| 精品人妻一区二区三区麻豆| 欧美日韩综合久久久久久| 美女主播在线视频| 中文字幕高清在线视频| 新久久久久国产一级毛片| 日韩,欧美,国产一区二区三区| 久久九九热精品免费| 大片电影免费在线观看免费| 欧美国产精品va在线观看不卡| 亚洲少妇的诱惑av| 夫妻性生交免费视频一级片| 两人在一起打扑克的视频| 精品高清国产在线一区| 亚洲少妇的诱惑av| 国产亚洲欧美在线一区二区| 女人精品久久久久毛片| 亚洲欧美一区二区三区久久| 精品亚洲乱码少妇综合久久| 久久中文字幕一级| 爱豆传媒免费全集在线观看| 国产精品久久久久成人av| 国产亚洲精品第一综合不卡| 中文字幕人妻丝袜制服| 亚洲欧洲国产日韩| 最近手机中文字幕大全| 久久精品熟女亚洲av麻豆精品| 国产成人精品在线电影| 久久久久久亚洲精品国产蜜桃av| 午夜91福利影院| videos熟女内射| 国产男女超爽视频在线观看| 可以免费在线观看a视频的电影网站| 91九色精品人成在线观看| 亚洲伊人色综图| 啦啦啦 在线观看视频| 视频在线观看一区二区三区| 欧美中文综合在线视频| 亚洲精品日本国产第一区| 精品国产一区二区三区四区第35| 中国美女看黄片| 亚洲精品国产色婷婷电影| 一级黄色大片毛片| 19禁男女啪啪无遮挡网站| 欧美日韩福利视频一区二区| 国产成人免费无遮挡视频| 欧美日韩黄片免| 免费在线观看完整版高清| 亚洲精品自拍成人| 国产高清videossex| 麻豆乱淫一区二区| 另类亚洲欧美激情| 免费人妻精品一区二区三区视频| 欧美精品av麻豆av| 久久久久久久大尺度免费视频| 19禁男女啪啪无遮挡网站| 国产极品粉嫩免费观看在线| 大片免费播放器 马上看| 晚上一个人看的免费电影| 十八禁网站网址无遮挡| 桃花免费在线播放| 美国免费a级毛片| 久久久国产欧美日韩av| 亚洲欧美精品自产自拍| 激情五月婷婷亚洲| 精品亚洲乱码少妇综合久久| 免费高清在线观看视频在线观看| 王馨瑶露胸无遮挡在线观看| 国产精品国产av在线观看| 制服诱惑二区| 王馨瑶露胸无遮挡在线观看| 亚洲国产看品久久| 欧美精品一区二区免费开放| 亚洲欧美一区二区三区久久| 午夜福利一区二区在线看| 久9热在线精品视频| 天天躁日日躁夜夜躁夜夜| avwww免费| 国产精品一国产av| 亚洲自偷自拍图片 自拍| 日韩电影二区| 波多野结衣一区麻豆| 99久久99久久久精品蜜桃| 青春草视频在线免费观看| 国产黄频视频在线观看| 无限看片的www在线观看| 精品人妻在线不人妻| 久久性视频一级片| av在线播放精品| 欧美精品高潮呻吟av久久| 亚洲国产欧美一区二区综合| 久久精品久久精品一区二区三区| 成年动漫av网址| 两性夫妻黄色片| netflix在线观看网站| 亚洲国产看品久久| 亚洲国产av新网站| 97人妻天天添夜夜摸| 人妻一区二区av| 十八禁人妻一区二区| 精品一区在线观看国产| 99国产精品99久久久久| 亚洲精品在线美女| 亚洲国产看品久久| 你懂的网址亚洲精品在线观看| 久久久精品国产亚洲av高清涩受| 脱女人内裤的视频| 啦啦啦啦在线视频资源| 宅男免费午夜| 天天躁夜夜躁狠狠久久av| 一本色道久久久久久精品综合| 热re99久久国产66热| 亚洲精品国产av蜜桃| 久久久久精品人妻al黑| 免费高清在线观看视频在线观看| av一本久久久久| 国产黄色视频一区二区在线观看| 日韩视频在线欧美| 纵有疾风起免费观看全集完整版| 国产成人av教育| 久久精品国产综合久久久| 午夜免费男女啪啪视频观看| 另类亚洲欧美激情| 久久中文字幕一级| 日本一区二区免费在线视频| xxxhd国产人妻xxx| 美女视频免费永久观看网站| 熟女av电影| 成人手机av| 高潮久久久久久久久久久不卡| 精品国产超薄肉色丝袜足j| 久久亚洲国产成人精品v| 18在线观看网站| 欧美另类一区| 日韩一区二区三区影片| 亚洲成人国产一区在线观看 | 国产亚洲av高清不卡| 日韩欧美一区视频在线观看| 51午夜福利影视在线观看| 午夜激情久久久久久久| 国产精品久久久久久精品电影小说| 巨乳人妻的诱惑在线观看| 亚洲av日韩在线播放| 日韩中文字幕视频在线看片| 欧美国产精品va在线观看不卡| 男人添女人高潮全过程视频| 美女主播在线视频| 亚洲午夜精品一区,二区,三区| 捣出白浆h1v1| 久久久久精品国产欧美久久久 | 亚洲国产看品久久| 18禁黄网站禁片午夜丰满| 久久久久网色| 90打野战视频偷拍视频| 国产片内射在线| 国产在线一区二区三区精| 男女边摸边吃奶| 亚洲成人手机| 国产精品二区激情视频| 啦啦啦在线观看免费高清www| 国产成人欧美| 1024视频免费在线观看| 婷婷色综合www| 国产伦理片在线播放av一区| 国产男女内射视频| 亚洲国产精品国产精品| 婷婷色综合大香蕉| 久久久久久免费高清国产稀缺| 最近最新中文字幕大全免费视频 | 大型av网站在线播放| 亚洲,一卡二卡三卡| av视频免费观看在线观看| 如日韩欧美国产精品一区二区三区| 王馨瑶露胸无遮挡在线观看| 国产成人91sexporn| 人人澡人人妻人| 亚洲精品国产av蜜桃| 亚洲av日韩在线播放| 久久精品久久久久久噜噜老黄| 高清欧美精品videossex| 亚洲成人免费av在线播放| 在线看a的网站| 国产片内射在线| 成年女人毛片免费观看观看9 | 丁香六月天网| 久热这里只有精品99| 1024视频免费在线观看| 久久人人爽av亚洲精品天堂| 性色av一级| 久久国产精品大桥未久av| 国产成人啪精品午夜网站| 美女视频免费永久观看网站| 99国产综合亚洲精品| 2018国产大陆天天弄谢| 中文字幕精品免费在线观看视频| 久久狼人影院| 欧美亚洲 丝袜 人妻 在线| 啦啦啦在线免费观看视频4| www.自偷自拍.com| 亚洲九九香蕉| 少妇的丰满在线观看| 亚洲精品一卡2卡三卡4卡5卡 | 亚洲成人国产一区在线观看 | 乱人伦中国视频| 人成视频在线观看免费观看| 中国国产av一级| 自线自在国产av| 精品福利永久在线观看| 夫妻午夜视频| 黄色 视频免费看| 黄频高清免费视频| 国产成人av激情在线播放| 亚洲少妇的诱惑av| 又大又爽又粗| 好男人视频免费观看在线| 在线观看一区二区三区激情| 在线观看免费日韩欧美大片| 大片免费播放器 马上看| 考比视频在线观看| 少妇人妻 视频| 久热爱精品视频在线9| 久久精品人人爽人人爽视色| 少妇的丰满在线观看| 女人被躁到高潮嗷嗷叫费观| 一级片免费观看大全| 99久久99久久久精品蜜桃| 天天躁狠狠躁夜夜躁狠狠躁| 久久久久久久久久久久大奶| 久久精品久久精品一区二区三区| 国产精品香港三级国产av潘金莲 | 亚洲国产欧美日韩在线播放| 欧美xxⅹ黑人| 日日爽夜夜爽网站| 欧美在线黄色| 波多野结衣一区麻豆| 成年人午夜在线观看视频| 欧美黄色片欧美黄色片| 久久久久视频综合| 建设人人有责人人尽责人人享有的| 成人亚洲精品一区在线观看| 啦啦啦在线观看免费高清www| 99久久综合免费| 久久亚洲精品不卡| 男人操女人黄网站| 国产成人精品久久二区二区免费| 国产av一区二区精品久久| 99热国产这里只有精品6| 亚洲欧美中文字幕日韩二区| 捣出白浆h1v1| 婷婷丁香在线五月| 女人被躁到高潮嗷嗷叫费观| 婷婷色麻豆天堂久久| 高清欧美精品videossex| 人人妻人人爽人人添夜夜欢视频| 久久精品国产a三级三级三级| kizo精华| 在线观看免费日韩欧美大片| 亚洲国产最新在线播放| 赤兔流量卡办理| 日本av免费视频播放| 亚洲av片天天在线观看| 赤兔流量卡办理| 亚洲伊人久久精品综合| 天堂俺去俺来也www色官网| 香蕉丝袜av| 久久ye,这里只有精品| 老汉色∧v一级毛片| 亚洲欧美一区二区三区黑人| 亚洲色图综合在线观看| 久久毛片免费看一区二区三区| 午夜老司机福利片| 9热在线视频观看99| 91精品三级在线观看| 色婷婷av一区二区三区视频| 97精品久久久久久久久久精品| 99精国产麻豆久久婷婷| 精品一区在线观看国产| 99久久人妻综合| 波多野结衣一区麻豆| 下体分泌物呈黄色| 亚洲精品美女久久av网站| 国产成人啪精品午夜网站| 美女视频免费永久观看网站| 亚洲一码二码三码区别大吗| 久久久精品94久久精品| 日本五十路高清| 日韩伦理黄色片| 777久久人妻少妇嫩草av网站| 十八禁网站网址无遮挡| 熟女少妇亚洲综合色aaa.| 亚洲国产欧美日韩在线播放| 90打野战视频偷拍视频| 多毛熟女@视频| 天天躁夜夜躁狠狠躁躁| 国产欧美亚洲国产| 欧美成狂野欧美在线观看| 亚洲av片天天在线观看| 久久亚洲国产成人精品v| 免费不卡黄色视频| 精品少妇一区二区三区视频日本电影| 久久女婷五月综合色啪小说| 免费看不卡的av| 成人三级做爰电影| 亚洲成人免费av在线播放| 久久这里只有精品19| 日本欧美国产在线视频| 国产成人精品久久二区二区91| 精品一区二区三区四区五区乱码 | 亚洲专区中文字幕在线| 9热在线视频观看99| 国产视频一区二区在线看| 精品人妻一区二区三区麻豆| 午夜福利视频在线观看免费| 涩涩av久久男人的天堂| 在线精品无人区一区二区三| 国产精品 国内视频| 黑人猛操日本美女一级片| 九色亚洲精品在线播放| 免费观看av网站的网址| 国产欧美亚洲国产| 国产精品久久久久久人妻精品电影 | 久久久久国产一级毛片高清牌| 亚洲精品av麻豆狂野| 一二三四在线观看免费中文在| 亚洲欧美色中文字幕在线| 国产亚洲欧美在线一区二区| 又大又爽又粗| 日韩制服骚丝袜av| 黄色a级毛片大全视频| 欧美国产精品va在线观看不卡| www.自偷自拍.com| www.999成人在线观看| 国产成人精品久久二区二区91| 国产97色在线日韩免费| 啦啦啦中文免费视频观看日本| 在线 av 中文字幕| 无遮挡黄片免费观看| 国产精品.久久久| 亚洲人成电影免费在线| 丰满人妻熟妇乱又伦精品不卡| 亚洲欧美清纯卡通| 国产成人系列免费观看| 色94色欧美一区二区| 满18在线观看网站| 国产一区亚洲一区在线观看| 欧美人与性动交α欧美软件| 国产在线观看jvid| 国产精品av久久久久免费| 日本wwww免费看| 一区二区三区四区激情视频| 一区二区三区激情视频| 久久久精品免费免费高清| 亚洲欧美成人综合另类久久久| 精品国产国语对白av| 欧美在线黄色| 在线观看免费日韩欧美大片| svipshipincom国产片| 亚洲成国产人片在线观看| av在线播放精品| 天天影视国产精品| 午夜av观看不卡| 欧美日韩国产mv在线观看视频| 久久精品国产亚洲av涩爱| 精品久久蜜臀av无| 超碰97精品在线观看| 亚洲精品美女久久av网站| 久久久久久久精品精品| 亚洲精品美女久久久久99蜜臀 | 久久精品久久久久久久性| 欧美精品一区二区大全| 真人做人爱边吃奶动态| 午夜精品国产一区二区电影| 亚洲av电影在线进入| a级毛片在线看网站| 国产免费现黄频在线看| 18在线观看网站| 91麻豆av在线| 不卡av一区二区三区| 天天躁狠狠躁夜夜躁狠狠躁| 欧美日韩亚洲综合一区二区三区_| 亚洲综合色网址| 黄色一级大片看看| 国产麻豆69| 人妻人人澡人人爽人人| 国产主播在线观看一区二区 | 亚洲综合色网址| 亚洲三区欧美一区| 十八禁网站网址无遮挡| bbb黄色大片| netflix在线观看网站| 欧美黑人精品巨大| 亚洲天堂av无毛| 国产免费一区二区三区四区乱码| 在线观看一区二区三区激情| 一级毛片黄色毛片免费观看视频| 熟女少妇亚洲综合色aaa.| 69精品国产乱码久久久| 真人做人爱边吃奶动态| 男人添女人高潮全过程视频| 久久久久久久久久久久大奶| 久久久精品94久久精品| 国产精品久久久久久精品古装| 亚洲精品美女久久久久99蜜臀 | 久久精品久久久久久久性| 国产欧美日韩精品亚洲av| 99精品久久久久人妻精品| 我要看黄色一级片免费的| 久久久久网色| 天天躁狠狠躁夜夜躁狠狠躁| 伊人亚洲综合成人网| 午夜激情久久久久久久| 777久久人妻少妇嫩草av网站| 日韩欧美一区视频在线观看| 日韩人妻精品一区2区三区| 两个人看的免费小视频| 久久精品久久久久久久性| 看十八女毛片水多多多| 久久久久视频综合| 下体分泌物呈黄色| 十八禁网站网址无遮挡| 成人国语在线视频| 国产精品久久久久成人av| 男女无遮挡免费网站观看| 久久99精品国语久久久| 曰老女人黄片| 久久精品国产亚洲av高清一级| 咕卡用的链子| 国产高清不卡午夜福利| 精品高清国产在线一区| 精品少妇黑人巨大在线播放| av一本久久久久| 精品一品国产午夜福利视频| 各种免费的搞黄视频| 99久久人妻综合| 精品一区二区三区四区五区乱码 | 女人久久www免费人成看片| 看免费av毛片| 老汉色av国产亚洲站长工具| 国产成人av激情在线播放| 91精品三级在线观看| 午夜免费鲁丝| 亚洲视频免费观看视频| xxx大片免费视频| 在线观看一区二区三区激情| 精品欧美一区二区三区在线| 国产日韩欧美亚洲二区| 又大又黄又爽视频免费| 飞空精品影院首页| 在线观看免费午夜福利视频| 在线观看免费高清a一片| 在线天堂中文资源库| 人人妻人人添人人爽欧美一区卜| 亚洲成av片中文字幕在线观看| 高潮久久久久久久久久久不卡| 亚洲男人天堂网一区| av国产精品久久久久影院| 亚洲av日韩精品久久久久久密 | av天堂在线播放| 99久久精品国产亚洲精品| 国产日韩欧美亚洲二区| 操美女的视频在线观看| 亚洲av成人不卡在线观看播放网 | 国产亚洲午夜精品一区二区久久| 久久精品aⅴ一区二区三区四区| 久久久精品国产亚洲av高清涩受| 黄色 视频免费看| 久久精品国产亚洲av高清一级| 国产在视频线精品| 丝袜美腿诱惑在线| 天天躁日日躁夜夜躁夜夜| 欧美日韩亚洲综合一区二区三区_| 国产精品久久久久成人av| 国产免费福利视频在线观看| 亚洲国产欧美网| 人体艺术视频欧美日本| 国语对白做爰xxxⅹ性视频网站| 免费女性裸体啪啪无遮挡网站| 老司机影院成人| av网站免费在线观看视频| 97精品久久久久久久久久精品| 欧美亚洲 丝袜 人妻 在线| 韩国高清视频一区二区三区| 一区二区三区精品91| 亚洲五月色婷婷综合| 天天躁夜夜躁狠狠久久av| 久热爱精品视频在线9| 亚洲激情五月婷婷啪啪| 狂野欧美激情性bbbbbb| 青草久久国产| 老汉色∧v一级毛片| 久久精品久久久久久噜噜老黄| 亚洲精品国产av蜜桃| 亚洲欧洲国产日韩| 999久久久国产精品视频| 国产麻豆69| 国产亚洲精品第一综合不卡| 国产男人的电影天堂91| 亚洲精品久久成人aⅴ小说| 国产精品三级大全| 久久天堂一区二区三区四区| 9色porny在线观看| 日韩,欧美,国产一区二区三区| av在线播放精品| 欧美日韩综合久久久久久| 精品久久久精品久久久| 中文字幕人妻丝袜制服| 热99国产精品久久久久久7| cao死你这个sao货| 亚洲五月色婷婷综合| 纵有疾风起免费观看全集完整版| 久热爱精品视频在线9| 中文欧美无线码| 午夜免费成人在线视频| 国产精品免费大片| 久久毛片免费看一区二区三区| 黄色怎么调成土黄色| 黄色一级大片看看| 久久精品亚洲熟妇少妇任你| 天天躁夜夜躁狠狠久久av| 久久久久久久大尺度免费视频| 日韩大片免费观看网站| 欧美变态另类bdsm刘玥| 高潮久久久久久久久久久不卡| 亚洲av日韩精品久久久久久密 | 日韩制服丝袜自拍偷拍| 国产一区亚洲一区在线观看| 国产av一区二区精品久久| 青青草视频在线视频观看| 人人妻人人澡人人爽人人夜夜| 欧美 亚洲 国产 日韩一| 欧美精品人与动牲交sv欧美| 99热全是精品| 黄色片一级片一级黄色片| 在线观看一区二区三区激情| 男女国产视频网站| 深夜精品福利| 中文字幕av电影在线播放| 美女脱内裤让男人舔精品视频| 欧美精品啪啪一区二区三区 |